Efficacy of Alpha Blockers in Relieving Symptoms of JJ Stent

Introduction: JJ stenting has been routinely used in endourology with a wide variety of implications. These stents have beneficial effects in postoperative period improving surgical outcome. Though they are widely used in urology practice, JJ stents cause lower urinary tract symptoms (LUTS) in majority of patients. The objective of this study was to test the hypothesis that alpha blockers reduce lower urinary tract symptoms (LUTS) after rigid ureterorenoscopy in postoperative time period up to 3 weeks. Study Design: It was a randomized clinical trial (RCT). Setting: The study was conducted in KRL hospital, Islamabad. Patients presenting in outpatient / emergency department were selected for the study. Duration of Study: Six months (15th July 2016 to 15th Jan’ 2017) Methods: A prospective randomized study was conducted in total 100 patients undergoing rigid ureterorenoscopy (URS). Patients were randomized into an intervention Group A and Control Group B. In Group A tamsulosin 0.4mg was given after rigid ureterorenoscopy, while in Group B no tamsulosin was given except placebo. Primary outcome were lower urinary tract symptoms (LUTS), which were measured by international prostate symptoms score (IPSS) up to 3 weeks postoperatively. Results: The mean IPSS at 3rd week in postoperative phase of rigid URS for Group A was 4.76± 4.14315 and in Group B was 27.28 ± 5.03879 with the P value of 0.0001 which was statistically significant and also less than 0.05. So IPSS was statistically lower in Group A as compared to Group B up to 3 weeks post operatively. In conclusion, a significant statistical difference was found for Double J (DJ) stent related symptoms between the two groups. Conclusion: Alpha blockers reduce lower urinary tract symptoms (LUTS) in postoperative period of rigid ureterorenoscopy up to 3 weeks.

Download Full-text

Continuous versus Intermittent Tamsulosin Therapy in Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Randomized Control Trial

Journal of Armed Forces Medical College Bangladesh ◽

10.3329/jafmc.v15i1.48635 ◽

2020 ◽

Vol 15 (1) ◽

pp. 22-26

Author(s):

SM Shameem Waheed ◽

Mohammad Abdur Rakib ◽

Md Shahidul Islam ◽

Mohammad Abdur Rakib ◽

Md Ashif Chowdhury ◽

...

Keyword(s):

Urinary Tract ◽

Benign Prostatic Hyperplasia ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Urinary Tract Symptoms ◽

Significant Difference ◽

Group A ◽

Group B ◽

Lower Urinary

Introduction: Benign prostatic hyperplasia (BPH) is the most common benign tumour in men. About 50% of men at the age of 50 years develop BPH and about half of them report to the doctors with some form of lower urinary tract symptoms (LUTS). Objectives: To see the therapeutic effect of Tamsulosin on alternate day administration in comparison to daily dose for men who had been suffering from LUTS due to BPH. Materials and Methods: This clinical trial was carried out at Combined Military Hospital, Dhaka in a consecutive fashion for about 18 months. A total of 152 patients were selected from outpatient department and after assessing them through inclusion and exclusion criteria and grouped randomly in three groups Group-A (50 patients), Group-B (50 patients) and Group C (52 patients); all the patients were treated with Tablet Tamsulosin (0.4mg) daily for first three months. Then next 15 months they were treated as; Group-A received Tablet Tamsulosin (0.4mg) daily, Group-B received Tablet Tamsulosin (0.4mg) every alternate day and Group C received placebo Tablet (Folic acid 5 mg) daily. Data were collected at the beginning and end of 3rd month, 4th month, 7th month and 18th month of study, in the form of international prostate symptom score (IPSS), maximum urinary flow per second (Qmax) and post-voidal residue (PVR). Results: This study showed that at the initial three month, IPSS score declined in all three groups, Qmax improved and PVR reduced in all groups. In next phase of study; in Group-A patient there was progressive and significant improvement of all parameters (IPSS, Qmax and PVR) at the end of study. In Group-B patient also showed similar result at the end of study. In Group-C patient showed statistically significant difference in outcome in relation to Group-A and Group-B i.e. more in IPSS, less in Qmax and increase in PVR. Conclusion: With this study it is clearly evident that tamsulosin (0.4mg) therapy significantly improves symptoms of men suffering for LUTS due to BPH. And alternate day therapy having similar therapeutic outcome in relation to every day therapy. Journal of Armed Forces Medical College Bangladesh Vol.15 (1) 2019: 22-26

Download Full-text

COMPARISON OF SOLIFENACIN VERSUS COMBINATION OF SOLIFENACIN AND TAMSULOSIN IN IMPROVING UNILATERAL DOUBLE-J STENT RELATED LOWER URINARY TRACT SYMPTOMS - A PROSPECTIVE RANDOMIZED CONTROL TRIAL

Pakistan Armed Forces Medical Journal ◽

10.51253/pafmj.v71i1.2617 ◽

2021 ◽

Vol 71 (1) ◽

pp. 45-50

Author(s):

Muhammad Tanveer Sajid ◽

Sami Ur Rehman ◽

Muhammad Akmal ◽

Hussain Ahmad ◽

Zahoor Iqbal Mirza ◽

...

Keyword(s):

Urinary Tract ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Armed Forces ◽

P Value ◽

Cross Sectional ◽

Urinary Tract Symptoms ◽

Group A ◽

Group B ◽

Lower Urinary

Objective: To compare Solifenacin versus solifenacin plus tamsulosin in terms of international prostate symptom score (IPSS) for lower urinary tract symptoms (LUTS) in patients with unilateral double-J (DJ) ureteric stents. Study Design: Comparative cross sectional study. Place and Duration of Study: Armed Forces Institute of Urology, Rawalpindi from Sep 2018 to Feb 2019. Methodology: A total of two hundred (n=200) patients of either gender aged 20-50 years, who underwentunilateral DJ stenting for different endourological procedures, were enrolled after satisfying inclusion/exclusioncriteria and then randomly allocated to group A (Solifenacin 5mg once daily (OD) ± placebo for 2 weeks) or group B (Solifenacin 5mg OD ± Tamsulosin 0.4 mg OD for 2 weeks) respectively. Baseline (1st post-operative day) and Post 02 weeks treatment IPSS was recorded and analyzed. Results: Mean age of presentation in group A and group B was 41.11 ± 6.45 vs 39.86 ± 5.34 years with p-value 0.14. Majority of patients in both groups were male (34% female in group A while 31% in group B, difference being statistically insignificant p 0.65). Baseline IPSS in group A and group B was 10.33 ± 2.72 vs 10.46 ± 3.12 with pvalue 0.76 (statistically insignificant) while post 02 weeks treatment IPSS in group A and B was 9.20 ± 2.67 vs 7.88 ± 2.63 respectively with p-value <0.001, the difference being statistically significant. Conclusions: Current study revealed significant advantage of combination therapy (solifenacin ± tamsulosin)compared with solifenacin monotherapy in lowering LUTS based on IPSS in patients having unilateral......

Download Full-text

Efficacy of Alpha Blockers in Relieving Symptoms of JJ Stent

10.47363/jsar/2021(1)115 ◽

2021 ◽

pp. 1-5

Author(s):

Hassan Mumtaz ◽

Keyword(s):

Urinary Tract ◽

Lower Urinary Tract Symptoms ◽

Postoperative Period ◽

Surgical Outcome ◽

Lower Urinary Tract ◽

Alpha Blockers ◽

Beneficial Effects ◽

Urinary Tract Symptoms ◽

Jj Stent ◽

Lower Urinary

Download Full-text

Efficacy of Alpha Blockers in Relieving Symptoms of JJ Stent

10.47363/jsar/2020(1)115 ◽

2021 ◽

pp. 1-5

Author(s):

Hassan Mumtaz ◽

◽

Hassan Mansoor ◽

Kashif Bangash ◽

◽

...

Keyword(s):

Urinary Tract ◽

Lower Urinary Tract Symptoms ◽

Postoperative Period ◽

Surgical Outcome ◽

Lower Urinary Tract ◽

Alpha Blockers ◽

Beneficial Effects ◽

Urinary Tract Symptoms ◽

Jj Stent ◽

Lower Urinary

Download Full-text

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis

Therapeutic Advances in Urology ◽

10.1177/1756287221993283 ◽

2021 ◽

Vol 13 ◽

pp. 175628722199328

Author(s):

Andrea Mari ◽

Alessandro Antonelli ◽

Luca Cindolo ◽

Ferdinando Fusco ◽

Andrea Minervini ◽

...

Keyword(s):

Systematic Review ◽

Urinary Tract ◽

Benign Prostatic Hyperplasia ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Safety And Efficacy ◽

Alpha Blockers ◽

Urinary Tract Symptoms ◽

Lower Urinary

Background: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are a bothersome frequent symptom in adult males. This systematic review analyzed the available evidence on the pharmacokinetic and pharmacodynamic features of alfuzosin, and its clinical efficacy both as monotherapy and in combination with other drugs for the treatment of male LUTS/BPH. Methods: A systematic review of the last 10 years was performed using the MEDLINE, EMBASE and Cochrane libraries in March 2020. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42020136120) and is available in full on the University of York website. Results: Alfuzosin is a quinazoline derivative and, although a nonspecific α1-blocker, exhibits a selective concentration in the prostate compared with plasma in patients with BPH. Three registration trials assessed the safety and efficacy of alfuzosin. The 10 mg daily formulation has a three-layered matrix containing the active substance between two inactive coats allowing a drug release over 20 h. Alfuzosin showed high tolerability, few vasodilatory effects and a low rate of ejaculation disorders over older alpha-blocking compounds thanks to the high uroselectivity of alfuzosin and its preferential concentration at urinary level. Six randomized clinical trials (RCTs) assessed efficacy and safety of alfuzosin versus other alpha-blockers ± placebo: three studies comparing with tamsulosin, one with doxazosin, and two with silodosin or tamsulosin. One RCT investigated the clinical outcomes of alfuzosin with finasteride, two with propiverine and two with phosphodiesterase-5 inhibitors. Conclusions: Alfuzosin is an effective drug for the treatment of LUTS/BPH, with a lower rate of sexual disorders compared with other alpha-blockers. Alfuzosin is also safe with low adverse events in case of concomitant antihypertensive therapy and in patients with cardiovascular morbidity. Safety and efficacy of alfuzosin has been reported also in case of combination therapy with antimuscarinic agents and PDE5i.

Download Full-text